Celldex Therapeutics, Inc. — Director's Dealing 2014

Dec 19, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2014-12-17

Reporting Person: van den Broek Richard (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-12-17	Common Stock, par value $0.001 per share	A	2000	—	Acquired	2000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-12-17	Non-Qualified Stock Option (right to buy)	$18.11	A	8000	Acquired	2024-12-16	Common Stock (8000)	Direct

Footnotes

F1: On December 17, 2014, the Company awarded 2,000 shares of the Company's common stock in the form of restricted stock award under the Celldex Therapeutics, Inc. 2008 Stock Option and Incentive Plan (the "Plan"), subject to time-based forfeiture restrictions.

F2: Represents an option grant by the Company pursuant to the Plan

F3: The option becomes exercisable in whole on December 17, 2015